Coiled Therapeutics plc
Research Coiled Therapeutics plc (COIL.L) on Bullrun: market cap GBX 3.09B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCOIL.L
- ExchangeLSE
- CountryUnited Kingdom
- SectorHealthcare
- IndustryBiotechnology
- CurrencyGBX
- Market capGBX 3.09B
- Financial periodFY2025
- RevenueGBP 0
- Net income-GBP 3.36M
- Free cash flow-GBP 645.62K
Valuation Snapshot
latest market cap is GBX 3.09B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | GBP 0 | -GBP 3.36M | -GBP 645.62K | n/a | -0.22 | GBP 78.05K | GBP 0 | GBP 2.42M |
| FY2024 | GBP 0 | -GBP 971.80K | -GBP 783.73K | n/a | -0.08 | GBP 337.11K | GBP 400.09K | GBP 4.89M |
| FY2023 | GBP 200.00K | -GBP 1.74M | -GBP 1.79M | 100.0% | -0.14 | GBP 537.32K | GBP 0 | GBP 5.50M |
| FY2022 | GBP 0 | -GBP 1.62M | -GBP 1.58M | n/a | -0.16 | GBP 2.32M | n/a | GBP 7.21M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-04 | GBX 3.09B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 GBX.
About Coiled Therapeutics plc
Coiled Therapeutics plc, a clinical-stage oncology company, develops and commercialises clinical-stage oncology therapeutics in the United Kingdom and internationally. The company's lead asset is AO-252, a first-in-class, small molecule inhibitor of TACC3, currently in a Phase I clinical trial for advanced solid tumours, including ovarian and prostate cancer.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Coiled Therapeutics plc's market cap?
Coiled Therapeutics plc's market capitalization is GBX 3.09B.
What does Coiled Therapeutics plc do?
Coiled Therapeutics plc, a clinical-stage oncology company, develops and commercialises clinical-stage oncology therapeutics in the United Kingdom and internationally. The company's lead asset is AO-252, a first-in-class, small molecule inhibitor of TACC3, currently in a Phase I clinical trial for advanced solid tumours, including ovarian and prostate cancer. The company also offers a STAT-6 siRNA programme targeting immunology indications such as asthma, fibrosis, eczema, and allergic disease, with plans for assessment towards Phase I clinical trials.